Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1827 1
1939 1
1946 1
1954 2
1957 1
1961 1
1964 3
1965 1
1969 4
1970 3
1971 4
1972 3
1973 2
1974 4
1975 23
1976 21
1977 31
1978 33
1979 38
1980 40
1981 38
1982 50
1983 54
1984 59
1985 56
1986 62
1987 65
1988 62
1989 100
1990 95
1991 102
1992 126
1993 113
1994 137
1995 119
1996 139
1997 116
1998 135
1999 136
2000 169
2001 177
2002 168
2003 150
2004 194
2005 230
2006 223
2007 261
2008 272
2009 233
2010 268
2011 213
2012 249
2013 301
2014 283
2015 311
2016 279
2017 345
2018 347
2019 388
2020 424
2021 486
2022 474
2023 535
2024 336

Text availability

Article attribute

Article type

Publication date

Search Results

8,526 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: 019451882.1
Page 1
Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
Lee J, Lim DH, Kim S, Park SH, Park JO, Park YS, Lim HY, Choi MG, Sohn TS, Noh JH, Bae JM, Ahn YC, Sohn I, Jung SH, Park CK, Kim KM, Kang WK. Lee J, et al. J Clin Oncol. 2012 Jan 20;30(3):268-73. doi: 10.1200/JCO.2011.39.1953. Epub 2011 Dec 19. J Clin Oncol. 2012. PMID: 22184384 Clinical Trial.
The XP/XRT/XP arm received two cycles of XP followed by 45-Gy XRT (capecitabine 1,650 mg/m2 per day for 5 weeks) and two cycles of XP. RESULTS: Of 458 patients, 228 were randomly assigned to the XP arm and 230 to the XP/XRT/XP arm. …
The XP/XRT/XP arm received two cycles of XP followed by 45-Gy XRT (capecitabine 1,650 mg/m2 per day for 5 weeks) and tw …
Xeroderma Pigmentosum.
Kraemer KH, DiGiovanna JJ, Tamura D. Kraemer KH, et al. 2003 Jun 20 [updated 2022 Mar 24]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. 2003 Jun 20 [updated 2022 Mar 24]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. PMID: 20301571 Free Books & Documents. Review.
The most common causes of death are skin cancer, neurologic degeneration, and internal cancer. The median age at death in persons with XP with neurodegeneration (29 years) was found to be younger than that in persons with XP without neurodegeneration (37 years). ... …
The most common causes of death are skin cancer, neurologic degeneration, and internal cancer. The median age at death in persons with XP
Xylan Plastic.
Jia S, Lv Z, Rao J, Lü B, Chen G, Bian J, Li M, Peng F. Jia S, et al. ACS Nano. 2023 Jul 25;17(14):13627-13637. doi: 10.1021/acsnano.3c02327. Epub 2023 Jul 13. ACS Nano. 2023. PMID: 37439501
Moreover, XP showed a low thermal expansion coefficient and excellent optical properties. Cytotoxicity and degradability tests demonstrated that XP had excellent nontoxicity and can be biodegraded in 60 days. ...
Moreover, XP showed a low thermal expansion coefficient and excellent optical properties. Cytotoxicity and degradability tests demons …
Xeroderma pigmentosum-Cockayne syndrome complex.
Natale V, Raquer H. Natale V, et al. Orphanet J Rare Dis. 2017 Apr 4;12(1):65. doi: 10.1186/s13023-017-0616-2. Orphanet J Rare Dis. 2017. PMID: 28376890 Free PMC article. Review.
There are four groups in XP-CS, and classification was available for 42 patients. Twenty-one were in the XP-G complementation group, 13 in XP-D, 5 in XP-B, and 3 in XP-F. ...However, one intriguing finding was that cancer incidence was lower in …
There are four groups in XP-CS, and classification was available for 42 patients. Twenty-one were in the XP-G complementation …
Sunlight, Vitamin D, and Xeroderma Pigmentosum.
Martens MC, Emmert S, Boeckmann L. Martens MC, et al. Adv Exp Med Biol. 2020;1268:319-331. doi: 10.1007/978-3-030-46227-7_16. Adv Exp Med Biol. 2020. PMID: 32918226 Review.
As UV radiation plays a critical role in the photosynthesis of vitamin D, stringent sun protection, as recommended for xeroderma pigmentosum (XP) patients, may impact their vitamin D levels.XP is a rare autosomal recessive disorder with a worldwide prevalence of 1 i …
As UV radiation plays a critical role in the photosynthesis of vitamin D, stringent sun protection, as recommended for xeroderma pigmentosum …
Meta-analysis of three randomized trials of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as first-line treatment for advanced gastric cancer.
Nishikawa K, Kawakami H, Shimokawa T, Fujitani K, Tamura S, Endo S, Kobayashi M, Kawada J, Kurokawa Y, Tsuburaya A, Yoshikawa T, Sakamoto J, Satoh T; for HERBIS-2, HERBIS-4A, XParTS I. I. study investigators. Nishikawa K, et al. Int J Clin Oncol. 2023 Nov;28(11):1501-1510. doi: 10.1007/s10147-023-02402-1. Epub 2023 Aug 27. Int J Clin Oncol. 2023. PMID: 37634209
BACKGROUND: S-1 plus cisplatin (SP) and capecitabine plus cisplatin (XP) are standard first-line regimens for advanced gastric cancer (AGC) worldwide. ...For the differentiated type, OS was significantly longer in the SP group (13.2 months) than in the XP group (11. …
BACKGROUND: S-1 plus cisplatin (SP) and capecitabine plus cisplatin (XP) are standard first-line regimens for advanced gastric cancer …
Xeroderma pigmentosum: beyond skin cancer.
Lichon V, Khachemoune A. Lichon V, et al. J Drugs Dermatol. 2007 Mar;6(3):281-8. J Drugs Dermatol. 2007. PMID: 17373189 Review.
Xeroderma pigmentosum (XP) is a rare, autosomal-recessive inherited disease that is found worldwide at a frequency of approximately 1:250,000. ...We present a review of the history, clinical manifestations, pathogenesis, diagnosis, and treatment of XP....
Xeroderma pigmentosum (XP) is a rare, autosomal-recessive inherited disease that is found worldwide at a frequency of approximately 1 …
Xeroderma Pigmentosum: A Model for Human Premature Aging.
Rizza ERH, DiGiovanna JJ, Khan SG, Tamura D, Jeskey JD, Kraemer KH. Rizza ERH, et al. J Invest Dermatol. 2021 Apr;141(4S):976-984. doi: 10.1016/j.jid.2020.11.012. Epub 2021 Jan 9. J Invest Dermatol. 2021. PMID: 33436302 Free PMC article. Review.
Poikiloderma, atypical lentigines, and skin cancers, the primary cutaneous features of XP, occur in the general population but at a much older age. Patients with XP also exhibit ocular changes secondary to premature photoaging, including ocular surface tumors and pt …
Poikiloderma, atypical lentigines, and skin cancers, the primary cutaneous features of XP, occur in the general population but at a m …
Simulational Tests of the Rouse Model.
Phillies GDJ. Phillies GDJ. Polymers (Basel). 2023 Jun 8;15(12):2615. doi: 10.3390/polym15122615. Polymers (Basel). 2023. PMID: 37376261 Free PMC article. Review.
We focus on Rouse model predictions for the mean-square amplitudes (Xp(0))2 and time correlation functions Xp(0)Xp(t) of the Rouse mode Xp(t). ...For small p (say, p3) (Xp(0))2 scales with p as p-2; for larger p, it scales as p-3. (ii) Rouse mod …
We focus on Rouse model predictions for the mean-square amplitudes (Xp(0))2 and time correlation functions Xp(0)Xp(t) o …
Shining a light on xeroderma pigmentosum.
DiGiovanna JJ, Kraemer KH. DiGiovanna JJ, et al. J Invest Dermatol. 2012 Mar;132(3 Pt 2):785-96. doi: 10.1038/jid.2011.426. Epub 2012 Jan 5. J Invest Dermatol. 2012. PMID: 22217736 Free PMC article. Review.
XP cells were found to have defects in seven of the proteins of the nucleotide excision repair pathway and in DNA polymerase eta. XP cells are hypersensitive to killing by UV radiation, and XP cancers have characteristic "UV signature" mutations. ...
XP cells were found to have defects in seven of the proteins of the nucleotide excision repair pathway and in DNA polymerase eta.
8,526 results